Hester Bios

Which are the latest news on Hester Bios?

Why is Hester Biosciences Ltd falling/rising?

As of 05-Sep, Hester Biosciences Ltd's stock price is rising to 2,408.70, reflecting a 9.84% increase. This rise is supported by strong performance against benchmarks and moving averages, despite a significant drop in delivery volume.

As of 05-Sep, Hester Biosciences Ltd's stock price is rising, currently at 2,408.70, reflecting a change of 215.85 or 9.84% increase. This upward movement is supported by several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 4.84% while the Sensex declined by 0.97%. Additionally, the stock has shown a significant performance today, outperforming its sector by 8.98% and achieving a consecutive gain over the last two days with a total return of 9.07% during this period.<BR><BR>The stock also reached an intraday high of Rs 2,524.9, marking a 15.14% increase at its peak. Despite a wide trading range of Rs 332.5, the stock has maintained trading above its 5-day, 50-day, 100-day, and 200-day moving averages, indicating a strong upward trend. However, it is worth noting that the delivery volume has decreased significantly, falling by 62.03% against the 5-day average, which may suggest a decline in investor participation. Nonetheless, the overall liquidity remains adequate for trading.<BR><BR>In summary, the combination of recent gains, strong performance relative to the sector and benchmark, and positive moving averages contribute to the rising stock price of Hester Biosciences Ltd.

Who are in the management team of Hester Bios?

The management team of Hester Bios includes Bhupendra V Gandhi (Chairman), Rajiv D Gandhi (CEO), and several independent and non-executive directors, totaling 11 members with diverse expertise.

The management team of Hester Bios includes the following individuals:<BR><BR>1. **Bhupendra V Gandhi** - Chairman & Non-Executive Director<BR>2. **Sanjiv D Gandhi** - Non-Executive & Non-Independent Director<BR>3. **Nina Gandhi** - Non-Executive Director<BR>4. **Sandhya Patel** - Independent Non-Executive Director<BR>5. **Ashok Bhadakal** - Independent Non-Executive Director<BR>6. **Ameet Desai** - Independent Non-Executive Director<BR>7. **Rajiv D Gandhi** - Executive Director, Managing Director, CEO, and Promoter<BR>8. **Ravin Gandhi** - Non-Executive & Non-Independent Director<BR>9. **Priya Rajiv Gandhi** - Executive Director<BR>10. **Anil Jain** - Independent Non-Executive Director<BR>11. **Jatin Yagneshbhai Trivedi** - Independent Non-Executive Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Hester Bios do?

Hester Biosciences Ltd is an Indian animal healthcare company focused on manufacturing poultry and large animal vaccines, with a market cap of INR 1,945 Cr. As of June 2026, it reported net sales of 77 Cr and a net profit of 97 Cr.

Overview: <BR>Hester Biosciences Ltd is a leading animal healthcare company in India, specializing in the manufacturing of poultry and large animal vaccines, and operates within the Pharmaceuticals & Biotechnology industry in the micro-cap market.<BR><BR>History: <BR>Hester Biosciences Ltd was incorporated in April 1987. The latest quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 77 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 97 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,945 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 36.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.48% <BR>Debt-Equity: 0.52 <BR>Return on Equity: 14.91% <BR>Price to Book: 5.40 <BR><BR>Contact Details: <BR>Address: 1st Flr PushpakPachvati Circle, Motilal Hirabhai Road Ahmedabad Gujarat : 380006 <BR>Tel: 91-079-26445107 <BR>Email: mail@hester.in <BR>Website: http://www.hester.in

Who are the peers of the Hester Bios?

Hester Bios' peers include Indoco Remedies, Venus Remedies, Windlas Biotech, Shukra Pharma, Syncom Formul, NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, and Sakar Healthcare. Venus Remedies leads in 1-year returns at 268.72%, while Hester Bios has a return of 11.55%.

Peers: The peers of Hester Bios are Indoco Remedies, Venus Remedies, Windlas Biotech, Shukra Pharma., Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Venus Remedies and Amrutanjan Healt, while Average management risk is found at Indoco Remedies, Windlas Biotech, Shukra Pharma., Hester Bios, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, and Sakar Healthcare. Growth is rated as Excellent for Shukra Pharma., Good for Venus Remedies, and Below Average for Indoco Remedies, Windlas Biotech, Hester Bios, Syncom Formul., NGL Fine Chem, Jagsonpal Pharma, Amrutanjan Healt, and Sakar Healthcare. Capital Structure is Excellent for Venus Remedies, Windlas Biotech, Shukra Pharma., Syncom Formul., NGL Fine Chem, and Jagsonpal Pharma, while Below Average is noted for Hester Bios and Indoco Remedies, and Average for Sakar Healthcare.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Venus Remedies at 268.72%, while the lowest is Amrutanjan Healt at -26.26%. Hester Bios has a 1-year return of 11.55%, which is significantly lower than Venus Remedies but higher than Amrutanjan Healt. Additionally, NGL Fine Chem and Amrutanjan Healt have negative six-month returns.

How big is Hester Bios?

As of 31st August, Hester Biosciences Ltd has a market capitalization of 1,945.00 Cr, with recent net sales of 325.74 Cr and a net profit of 136.18 Cr.

As of 31st August, Hester Biosciences Ltd has a market capitalization of 1,945.00 Cr, categorized as a Micro Cap.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 325.74 Cr and a Net Profit of 136.18 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, with Shareholder's Funds amounting to 360.24 Cr and Total Assets of 677.94 Cr.

Should I buy, sell or hold Hester Biosciences Ltd?

Are Hester Biosciences Ltd latest results good or bad?

Hester Biosciences Ltd's latest results show a significant net profit increase of 489.90% to ₹96.98 crores, largely due to one-time gains, but net sales declined by 8.17% year-on-year, raising concerns about operational challenges. Overall, while profit figures are impressive, the revenue decline suggests caution for future performance.

Hester Biosciences Ltd's latest results present a mixed picture. On one hand, the company reported a significant increase in net profit, which rose by 489.90% year-on-year to ₹96.98 crores. This impressive profit surge is largely attributed to exceptional items or one-time gains, rather than sustained operational performance.<BR><BR>On the other hand, net sales declined by 8.17% year-on-year, falling to ₹77.24 crores. This decline raises concerns about potential market share losses or challenges within the animal healthcare sector. Additionally, there was a notable 22.84% drop in sales compared to the previous quarter, indicating potential operational headwinds.<BR><BR>While the operating margin improved to 29.48%, reflecting effective cost management, the overall revenue contraction and the reliance on non-recurring profit boosts suggest caution. The company's ability to maintain this performance in future quarters is uncertain, especially given the rising interest costs and the need for improved capital efficiency.<BR><BR>In summary, while the profit figures are striking, the underlying operational challenges and revenue decline indicate that the results are not entirely positive. Investors should closely monitor future performance to assess whether the company can achieve sustainable growth.

When is the next results date for Hester Biosciences Ltd?

The next results date for Hester Biosciences Ltd is 30 July 2026.

The next results date for Hester Biosciences Ltd is scheduled for 30 July 2026.

Is Hester Bios technically bullish or bearish?

As of November 24, 2025, Hester Bios is in a strong bearish trend, indicated by bearish MACD readings, moving averages, and KST across multiple time frames, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 24 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Hester Bios is bearish with a strong indication. Key indicators driving this stance include bearish MACD readings on both weekly and monthly time frames, bearish moving averages on the daily chart, and a bearish KST on both weekly and monthly levels. The Bollinger Bands also reflect a bearish trend on the weekly chart and a mildly bearish stance on the monthly chart. Although Dow Theory shows a mildly bullish signal on the weekly, the overall bearish indicators dominate the analysis.

How has been the historical performance of Hester Bios?

Hester Bios has shown steady growth in net sales and profitability, with net sales increasing from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025, and profit after tax rising from INR 16.56 crore to INR 24.73 crore in the same period, despite some fluctuations in expenses and cash flow. Total assets and liabilities decreased slightly, while cash flow from operating activities improved significantly.

Answer:<BR>The historical performance of Hester Bios shows a steady growth in net sales and profitability over the years, with some fluctuations in specific metrics.<BR><BR>Breakdown:<BR>Hester Bios has demonstrated a consistent increase in net sales from INR 178.07 crore in March 2019 to INR 311.10 crore in March 2025. Total operating income has followed a similar trend, reaching INR 311.10 crore in March 2025, up from INR 266.09 crore in March 2023. The company's total expenditure, excluding depreciation, was INR 250.05 crore in March 2025, slightly down from INR 250.90 crore in March 2024. Operating profit (PBDIT) has shown resilience, with a figure of INR 64.97 crore in March 2025, compared to INR 64.29 crore in March 2024. Profit before tax was INR 35.47 crore in March 2025, an increase from INR 27.34 crore in March 2024, while profit after tax rose to INR 24.73 crore from INR 16.56 crore in the previous year. The company's total assets were INR 653.38 crore in March 2025, a decrease from INR 662.35 crore in March 2024, and total liabilities also decreased to INR 653.38 crore from INR 662.35 crore. Cash flow from operating activities improved significantly to INR 64.00 crore in March 2025 from INR 48.00 crore in March 2024, while net cash outflow was recorded at INR -6.00 crore in March 2025. Overall, Hester Bios has shown a positive trajectory in sales and profitability, despite some fluctuations in expenses and cash flow.

Is Hester Bios overvalued or undervalued?

As of April 1, 2025, Hester Bios is considered overvalued with a very expensive valuation grade, reflected in its high PE ratio of 57.23 and EV to EBITDA ratio of 29.14, despite a recent stock return of 15.37% that outperformed the Sensex, while its long-term performance has underperformed the index.

As of 1 April 2025, Hester Bios has moved from an expensive to a very expensive valuation grade. The company is currently considered overvalued. Key ratios include a PE ratio of 57.23, an EV to EBITDA ratio of 29.14, and a Price to Book Value of 5.01. In comparison to its peers, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Divi's Lab shows a significantly higher PE ratio of 79.33 and an EV to EBITDA of 57.35, indicating that Hester Bios is trading at a premium relative to some peers.<BR><BR>Despite a recent stock return of 15.37% over the past month, which outperformed the Sensex's 3.87%, the long-term performance shows that Hester Bios has underperformed the index year-to-date and over three years. This suggests that the current valuation may not be justified given the company's inconsistent performance relative to both its peers and the broader market.

Who are the top shareholders of the Hester Bios?

The top shareholders of Hester Bios include promoter Rajiv Dinesh Gandhi with 10.47% ownership, while public shareholder Kuntal Hasmukhlal Shah holds 3.17%. Individual investors own 32.64%, and foreign institutional investors hold 0.87%.

The top shareholders of Hester Bios include the promoters, with Rajiv Dinesh Gandhi being the promoter with the highest holding at 10.47%. The company has no pledged promoter holdings. In terms of public shareholders, Kuntal Hasmukhlal Shah holds the highest stake at 3.17%. Additionally, individual investors collectively hold 32.64% of the shares. There are also 20 foreign institutional investors (FIIs) who hold a total of 0.87%, and mutual funds are represented by two schemes, holding 0.0%.

What is the bonus history of the Hester Bios?

Hester Biosciences Ltd announced a 1:2 bonus issue on September 27, 2012, with a record date of September 29, 2012, meaning shareholders received one additional share for every two shares held.

Hester Biosciences Ltd has a bonus history that includes a 1:2 bonus issue announced on September 27, 2012. The record date for this bonus was September 29, 2012. This means that for every two shares held, shareholders received one additional share as a bonus. If you have any more questions about Hester Bios or need further details, feel free to ask!

Has Hester Bios declared dividend?

Hester Biosciences Ltd has declared a 60% dividend, amounting to ₹6 per share, with an ex-date of August 22, 2024. While the company shows mixed total returns over various periods, it has experienced significant declines in the short term but positive returns over the longer term.

Hester Biosciences Ltd has declared a 60% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 60%<BR>- Amount per share: 6<BR>- Ex-date: 22 Aug 24<BR><BR>Dividend Yield: 0.32%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -25.97%, the dividend return was 0%, resulting in a total return of -25.97%.<BR><BR>Over the past year, the price return was 4.14%, with a dividend return of 0.32%, leading to a total return of 4.46%.<BR><BR>In the 2-year period, the price return was 14.47%, the dividend return was 0.86%, culminating in a total return of 15.33%.<BR><BR>For the 3-year period, the price return was -18.58%, the dividend return was 1.15%, which resulted in a total return of -17.43%.<BR><BR>In the last 4 years, the price return was -29.74%, with a dividend return of 1.29%, leading to a total return of -28.45%.<BR><BR>Over the 5-year period, the price return was 47.13%, the dividend return was 3.36%, resulting in a total return of 50.49%.<BR><BR>Overall, Hester Biosciences Ltd has declared a significant dividend, but the total returns over various periods show mixed performance, with notable declines in the short term and positive returns over the longer term.